HomeMy WebLinkAboutSH22-011 - WA STATE HCA MOUD IN JAILS - AMENDMENT 5 FULLY EXECUTEDHCA Contract No. K5885-05 Page 1 of 13
CONTRACT
AMENDMENT
HCA Contract No.: K5885
Amendment No.: 05
THIS AMENDMENT TO THE CONTRACT is between the Washington State Health Care Authority and the party
whose name appears below, and is effective as of the date set forth below.
CONTRACTOR NAME CONTRACTOR doing business as (DBA)
Kittitas County Kittitas County Sheriff-Jail
CONTRACTOR ADDRESS CONTRACTOR CONTRACT MANAGER
205 W 5th Avenue, Suite 1
Ellensburg, WA 98926
Name: Edward Buntin
Email: edward.buntin@co.kittitas.wa.us
AMENDMENT START DATE CONTRACT END DATE
July 1, 2026 June 30, 2027
PRIOR MAXIMUM CONTRACT AMOUNT AMOUNT OF INCREASE TOTAL MAXIMUM COMPENSATION
$1,226,775 $209,000 $1,435,775
WHEREAS, HCA and Contractor entered into Contract K5885 for the development and implementation of the
Medication for Opioid Use Disorder (MOUD) and Medications for Alcohol Use Disorder (MAUD) in Jails
programs, and;
WHEREAS, HCA and Contractor wish to amend the Contract pursuant to Section 4.3, Amendments, to extend
the Contract term, increase funding, and incorporate a revised and restated Statement of Work;
THEREFORE, the parties agree the Contract is amended as follows:
1. Contract Section 2, Definitions, two (2) new defined terms are incorporated in alphabetical order. The
new defined terms are as follows:
“Informed Refusal” is when an individual refuses treatment after an explanation of the treatment is
provided including, its benefits and risks, alternatives, addressing the individual’s concerns and
exploration of any reasonable way of addressing the concerns to avoid refusal, and explanation of the
risks of refusal, all this provided in a manner that is comprehensible by the individual.
“Appears Unwell” means to demonstrate signs, symptoms, or indications observable by a layperson
that (1) indicate an individual may be sick (physically or psychologically); or (2) in the case of a patient
who has already been assessed by a qualified health care professional, indicate the individual’s condition
is worsening, becoming unstable, or becoming a danger to themselves or others.
2. Contract Section 3.2, Term, subsection 3.2.1, is amended to extend the Contract term as follows:
3.2.1 The initial term of the Contract will commence on March 1, 2022, and continue through June 30,
2027, unless terminated sooner as provided herein.
3. Contract Section 3.3, Compensation, subsection 3.3.1 is amended to reflect the $209,000 increase in
funding, subsection 3.3.1 now reads as follows:
3.3.1 The parties have determined the cost of accomplishing the work herein will not exceed
$1,435,775, inclusive of all fees, taxes, and expenses. Compensation for satisfactory performance
of the work will not exceed this amount unless the parties agree to a higher amount through an
amendment.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 2 of 13
4. A new Schedule A-5, Statement of Work, is added to prevent redundancy between the previous
Schedule A(s), Statement(s) of Work, while also incorporating updates. In the event of an inconsistency
the revised and restated Schedule A-5, Statement of Work, shall supersede all previous Schedule A(s),
Statement(s) of Work.
The revised and restated Schedule A-5, Statement of Work, is attached hereto and by this reference is
incorporated into the Contract.
5. A new Attachment 1-A, EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report, is added
to provide Contractor with the new reporting template to be required beginning July 1, 2026. The updated
Attachment 1-A, EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report, is attached
hereto and by this reference is incorporated into the Contract.
6. This Amendment is effective July 1, 2026, (“Effective Date”).
7. All capitalized terms not otherwise defined herein have the meaning ascribed to them in the Contract.
8. All other terms and conditions of the Contract remain unchanged and in full force and effect.
The parties signing below warrant that they have read and understand this Amendment and have authority to
execute the Amendment. This Amendment will be binding on HCA only upon signature by both parties.
CONTRACTOR SIGNATURE PRINTED NAME AND TITLE DATE SIGNED
HCA SIGNATURE PRINTED NAME AND TITLE DATE SIGNED
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Deputy Contracts Administrator 5/26/2026Andria Howerton
Sheriff
Clay Myers 5/26/2026
HCA Contract No. K5885-05 Page 3 of 13
SCHEDULE A-5
Statement of Work
1. PURPOSE
To support a comprehensive treatment program for incarcerated individuals with Opioid Use Disorder (OUD)
and Alcohol Use Disorder (AUD), beginning with screening upon entry and ending with seamless transition to
care in the community, with use of Medications for Opioid Use Disorder (MOUD) and Medications for Alcohol
Use Disorder (MAUD) at its core.
This Contract supports RCW 71.24.599: Opioid use disorder—City and county jails—Funding. (wa.gov).
Health Equity - This program also intends to address inequities in treatment and recovery services by
providing medically necessary treatment to incarcerated individuals. Programs should understand cultural
barriers and provide culturally appropriate services. Additionally, this program intends to identify stigma and
educate to ensure ongoing collaboration and openness to change.
2. PERFORMANCE EXPECTATIONS
In addition to the performance expectations outlined in Contract Section 3.1, Performance Expectations, the
following expectations are also required, as applicable:
2.1. Treatment Requirements for American Indian/Alaska Native (AI/AN) Individuals
For American Indian/Alaska Native (AI/AN) individuals receiving Medications for Opioid Use Disorder
(MOUD) and/or Medications for Alcohol Use Disorder (MAUD) services, Contractor, shall coordinate
with the individual’s Indian Health Care Provider (IHCP) to ensure the IHCP can participate in treatment
and discharge planning, including continuity of care in the nearest IHCP clinically appropriate setting.
3. WORK EXPECTATIONS
Contractor shall ensure funds are responsibly used towards the Opioid Use Disorder (OUD) and Alcohol Use
Disorder (AUD) treatment programs in the jail and provide the community standard of care, including, at a
minimum, the following core components:
3.1. General Requirements
3.1.1. Unless otherwise stated in this Statement of Work, Section 3, Work Expectations, Contractor
shall follow Guidelines for Managing Substance Withdrawal in Jails.
3.1.2. All refusals of care required under this contract must be Informed Refusals, one element of
which is that the individual must have decision-making capacity.
3.1.2.1. If an individual expresses a desire to refuse a treatment, appears well, and there is no
urgency to the treatment, treatment may be delayed until an appropriately licensed
professional determines they have decision-making capacity and obtains an Informed
Refusal.
3.1.2.2. If an individual expresses a desire to refuse a treatment (i.e., someone who then
needs to undergo an Informed Refusal) and either appears unwell or the treatment is
urgent, Contractor will arrange for immediate evaluation of the individual’s decision-
making capacity (i.e., on-site or at a community hospital), and, if they have such
capacity, immediately execute an Informed Refusal.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 4 of 13
a. If sent to a community hospital, Contractor shall not accept the individual back at
the jail until it is clinically safe to do so, and they have regained decision-making
capacity.
3.1.2.3. Decision-making capacity shall only be determined by a medical or mental health
prescriber (e.g., physician, nurse practitioner, physician assistant) or a licensed mental
health professional at the master’s level or higher. Informed Refusal shall only be
executed by a prescriber.
3.2. Intake
3.2.1. Screen all newly admitted individuals for risk of acute withdrawal from opioids and alcohol upon
intake.
3.2.2. MOUD1, MAUD 2, and other medications which support the relief of withdrawal symptoms, such
as alpha-2 adrenergic agonists (e.g., lofexidine), anti-emetics, anti-diarrheals, analgesics, and
fluid and electrolyte replacement (e.g., Gatorade®) must be offered to individuals at no charge
to the individual.
3.2.3. Offer initiation of MOUD treatment to individuals who are physically dependent on opioids, may
have withdrawal symptoms, or have disclosed recent use and anticipate withdrawal. Facilities
shall not require tapering from the illicit opioid unless clinically indicated.
3.2.4. Offer treatment for withdrawal with benzodiazepines to individuals entering the facility who are
physically dependent on alcohol, if clinically appropriate.
3.2.5. Continue MOUD and MAUD for individuals who are already taking these medications upon
entering the facility. Continue the individual on the same medication at the same dose unless
ordered otherwise by the prescriber based on clinical need, unless one of the following
exceptions is applicable:
3.2.5.1. Injectable long-acting naltrexone may be converted to an equivalent oral dose until just
prior to release at which time the injectable form shall be restarted.
3.2.5.2. Injectable long-acting buprenorphine may be converted to an equivalent oral dose until
just prior to release at which time the injectable form shall be restarted.
3.2.5.3. Oral buprenorphine may be converted to any of the three formulations available: film,
tablet with naloxone, or tablet without naloxone.
3.2.5.4. If the individual is not pregnant, methadone may be transitioned to buprenorphine if
one of the following is applicable:
a. Contractor is not a licensed Opioid Treatment Program (OTP) and the nearest OTP
willing to collaborate with the jail to provide methadone is not within reasonable
driving distance from the jail, and the jail does not have nursing staff on site seven
1 Methadone, buprenorphine, naltrexone
2 Naltrexone, acamprosate
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 5 of 13
(7) days a week. The individual must be started back on methadone prior to
release if they plan to resume methadone in the community.
b. There is no OTP within reasonable distance of the individual’s release residence.
3.2.5.5. Though MOUD/MAUD must not be discontinued on a policy or administrative basis
because of the presence of other illicit or controlled substances, administration of the
community-based MOUD or MAUD may be adjusted if clinically necessary due to
pharmacologic risks of drug-drug interaction.
3.2.6. Contractor shall screen for OUD and AUD without physical dependence (i.e., without a risk of
acute withdrawal) and history of opioid overdose, soon after intake.
3.2.7. Educate individuals on treatment choices and the process for continuation of access to
MOUD/MAUD during incarceration and upon release.
3.2.8. Make available and offer treatment using some formulation of methadone, buprenorphine, or
naltrexone based on a mutually agreed-upon plan between the prescriber and the individual.
The plan must take into consideration, among other clinically relevant factors, the availability of
specific medications at their residence of release.
3.2.8.1. Contractor may provide naltrexone or buprenorphine in oral formulation, with or without
naloxone while the individual is incarcerated but must offer an oral formulation of
buprenorphine WITH naloxone unless there is a clinical reason not to do so, e.g., the
individual is allergic to naloxone at release.
3.2.9. Contractor shall not allow an individual to undergo opioid withdrawal, including withdrawal using
a tapering dose of buprenorphine or methadone, unless the individual provides an Informed
Refusal of continuing maintenance MOUD treatment after withdrawing or the individual elects
MOUD treatment with naltrexone.
3.2.9.1. In either case, Contractor will offer the individual tapering doses of buprenorphine or
methadone supplemented, as necessary, with alpha-2 adrenergic agonists (e.g.,
lofexidine), anti-emetics, anti-diarrheals, analgesics, fluid and electrolyte replacement
(e.g., Gatorade®).
3.2.9.2. Initiation of buprenorphine or methadone, whether for maintenance or for withdrawal,
must not be delayed for administrative reasons, e.g., unavailability of a prescriber,
beyond when they are clinically indicated to be started.
3.3. During Incarceration
3.3.1. Offer initiation of maintenance MOUD/MAUD to individuals who did not start MOUD/MAUD for
acute opioid or alcohol withdrawal as identified at intake, e.g., individuals with OUD but without
physical dependence, or individuals with AUD who underwent withdrawal.
3.3.1.1. For all individuals initiation should begin soon enough to attempt stabilization of dosing
prior to release.
3.3.1.2. For individuals with a history of opioid overdose, initiation should begin as soon as
possible after identified.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 6 of 13
3.3.2. Educate individuals on treatment choices and the process for continuation of access to
MOUD/MAUD during incarceration and upon release.
3.3.3. Contractor shall not use alternate-day or “balloon” dosing of buprenorphine (i.e., administering a
dose of medication on one (1) day which is intended to last for two (2) or more days).
3.3.4. Administer methadone and buprenorphine more often than one dose daily if clinically
necessary, e.g., in some pregnant or post-partum individuals, those who metabolize the
medication faster, and individuals who have side effects from large single doses.
3.3.5. Offer counseling to individuals for their OUD/AUD if they are expected to remain in jail for longer
than one (1) month. Provide MOUD/MAUD regardless of the individual’s willingness to
participate in counseling.
3.3.6. There may be reasons an individual will not continue MOUD/MAUD in the community, such as
no available treatment provider in the community to which the individual is released. If the
individual will not continue MOUD/MAUD in the community, the decision when or if to
discontinue MOUD/MAUD prior to release must be based on a mutually agreed-upon decision
between the individual and the prescriber and must consider factors, including but not limited to,
the risks of opioid misuse or overdose during incarceration, and the individual's willingness to
receive a four-week (4-week) dose of an extended-release injectable buprenorphine just prior to
release which will provide a safe, tapered withdrawal.
3.4. Release
Contractor must accomplish the following prior to each individual’s release from jail:
3.4.1. Complete release planning and reentry coordination as soon as possible after admission to
ensure an effective plan is in place prior to release, including in the event of an unexpected
release of an individual who needs continued treatment and services.
3.4.2. Provide at least two (2) doses of an opioid reversal agent (e.g., naloxone or Narcan®) and
training on how to administer the medication to all individuals with OUD.
3.4.3. Schedule the first community appointment with a treatment facility for continuation of MOUD or
MAUD.
3.4.4. Provide in hand, upon release, and at no cost to the individual, a sufficient number of doses of
MOUD and/or MAUD to bridge the individual until the scheduled MOUD/MAUD follow-up
appointment at the selected community treatment facility.
3.4.4.1. If an individual is on a long-acting injectable medication, the Contractor will ensure the
timing of the injectable medication ensures sustained treatment effect to bridge the
individual to the scheduled MOUD/MAUD follow-up appointment at the selected
community treatment facility.
3.4.4.2. If an individual is at risk of being released directly from court, inform them prior to
going to court that they may request to be transported back to jail by staff to receive
these medications prior to going home.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 7 of 13
3.4.4.3. In situations where a follow-up appointment upon release cannot be made, e.g., after-
hours bail-out, give the individual enough medication to last until the next available
appointment at the community treatment. If the appointment date is unknown or cannot
be reliably estimated, give the individual a 30-day supply at minimum.
3.4.4.4. In situations where medications cannot be provided upon release, e.g., unscheduled
release at a time when medical staff are not present in jail, Contractor must ensure the
following:
a. The individual is informed that they may either return to the jail in the morning to
receive bridge medications; or
b. If no medical staff are present the following day, call in a prescription for the same
bridge medication to a local pharmacy, at no cost to the individual.
3.4.5. Assist Medicaid-eligible individuals to sign up for Medicaid or assist individuals whose Medicaid
coverage has been terminated to reestablish coverage.
3.4.6. For any individual with Medicaid coverage, work cooperatively with the individual’s Managed
Care Organizations (MCO) to facilitate re-entry benefits and continued treatment with a
community partner, including but not limited to allowing the MCO’s agent timely access to the
jail and the individual.
3.5. Contract Management
3.5.1. Ensure operation specific tools, such as job descriptions, policies and procedures, and
statements of work, are developed, and staff are adequately trained, to ensure consistent and
appropriate practice.
3.5.2. Attend monthly meetings with the HCA Contract Manager to discuss Contract requirements,
compliance, and problem-solving. Attend additional meetings as required or deemed necessary
by the HCA Contract Manager.
3.5.3. Contractor shall cooperate with periodic site visits by the HCA Contract Manager or designee
and make all relevant records and personnel available.
4. REPORTING
Contractor shall complete performance monitoring activities, including the submission of timely and accurate
data reports to the HCA Contract Manager, utilizing the HCA provided templates. Further evaluation,
including on- and off-site data collection, may be conducted by HCA or an HCA-designated third party.
Reporting shall include, but is not limited to, the following:
4.1. Monthly Progress Reports
4.1.1. Due no later than the 10th day of the month following the month in which the services being
reported were provided.
4.1.2. See Schedule A-5, EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 8 of 13
4.2. Monthly Data Collection Spreadsheet
4.2.1. Due no later than the 10th day of the month following the month in which the services being
reported were provided.
4.2.2. See Attachment 2, MOUD Monthly Data Collection Spreadsheet.
4.3. Data Collection Format
4.3.1. HCA anticipates shifting the data collection format from MFT to Program Data Acquisition
Management and Storage (PDAMS) system during the term of this Contract. Contractor shall
continue to collect data via Managed File Transfer (MFT) method until notified otherwise by the
HCA Contract Manager in writing.
4.3.1.1. HCA Contract Manager shall notify Contractor of this change no less than ten (10)
Business Days before implementing the new collection format.
5. COST REIMBURSEMENT
The payment format for this Contract is established as cost reimbursement. Reports and receipts must be
submitted monthly with each A-19 invoice, as identified in this section and in Contract Section 3.4, Invoice
and Payment.
5.1. Allowable Expenses
Only purchases and staff time which are not part of a Medicaid billable service are allowable. Refer to
the following documents for Medicaid billing guidance and fee schedules:
5.1.1. Reentry from a carceral setting | Washington State Health Care Authority
5.1.2. Reentry Initiative Policy and Operations Guide
5.1.3. Provider billing guides and fee schedules | Washington State Health Care Authority
5.1.4. Email questions to hcareentrydemonstrationproject@hca.wa.gov
5.2. Monthly Estimated Costs
5.2.1. The estimated monthly cost reimbursement is as follows:
5.2.1.1. July 1, 2026 – June 30, 2027
Monthly Estimated Cost Number of Months Total Costs
$17,416 12 $209,000
5.2.2. Adjustments revising twenty-five percent (25%) or more of the Monthly Estimated Costs as
identified in this section 5.2 must be submitted to the HCA Contract Manager or designee for
approval in writing, via email, at least fifteen (15) Business Days prior to expending the adjusted
funds.
5.2.3. HCA approval must be granted, in writing, prior to expending funds.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 9 of 13
5.3. Invoicing
Invoices must be submitted in conjunction with the monthly reports identified in this Statement of Work,
Section 4, Reporting, and as follows:
5.3.1. Invoices shall be due no later than the tenth (10th) day of the month following the month in which
the expenses being invoiced were expended; and
5.3.2. As outlined in Contract Section 3.4, Invoice and Payment.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 10 of 13
ATTACHMENT 1-A
EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report
NOTE: Example below provided for reference only, the HCA Contract Manager will provide the fillable form for
Contractor use prior to the July 1, 2026, implementation date.
CONTRACTOR NAME: PROJECT MANAGER(S):
MONTH REPORTING ON: CONTRACT FUNDING START: CONTRACT FUNDING END:
July 1, 2026 June 30, 2027
1. INTAKE
☐ Screen all newly admitted individuals for risk of acute withdrawal from opioids and alcohol upon intake.
☐ MOUD3, MAUD 4, and other medications which support the relief of withdrawal symptoms, such as
alpha-2 adrenergic agonists (e.g., lofexidine), anti-emetics, anti-diarrheals, analgesics, and fluid and
electrolyte replacement (e.g., Gatorade®) must be offered to individuals at no charge to the individual.
☐ Offer initiation of MOUD treatment to individuals who are physically dependent on opioids, may have
withdrawal symptoms, or have disclosed recent use and anticipate withdrawal. Facilities shall not
require tapering from the illicit opioid unless clinically indicated.
☐ Offer treatment for withdrawal with benzodiazepines to individuals entering the facility who are
physically dependent on alcohol, if clinically appropriate.
☐ Continue MOUD and MAUD for individuals who are already taking these medications upon entering the
facility. Continue the individual on the same medication at the same dose unless ordered otherwise by
the prescriber based on clinical need, unless one of the following exceptions is applicable:
• Injectable long-acting naltrexone may be converted to an equivalent oral dose until just prior to
release at which time the injectable form shall be restarted.
• Injectable long-acting buprenorphine may be converted to an equivalent oral dose until just prior to
release at which time the injectable form shall be restarted.
• Oral buprenorphine may be converted to any of the three formulations available: film, tablet with
naloxone, or tablet without naloxone.
• If the individual is not pregnant, methadone may be transitioned to buprenorphine if one of the
following is applicable:
o Contractor is not a licensed Opioid Treatment Program (OTP) and the nearest OTP willing to
collaborate with the jail to provide methadone is not within reasonable driving distance from the
jail, and the jail does not have nursing staff on site seven (7) days a week. The individual must
be started back on methadone prior to release if they plan to resume methadone in the
community.
o There is no OTP within reasonable distance of the individual’s release residence.
3 Methadone, buprenorphine, naltrexone
4 Naltrexone, acamprosate
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 11 of 13
Though MOUD/MAUD must not be discontinued on a policy or administrative basis because of the presence
of other illicit or controlled substances, administration of the community-based MOUD or MAUD may be
adjusted if clinically necessary due to pharmacologic risks of drug-drug interaction.
☐ Contractor shall screen for OUD and AUD without physical dependence (i.e., without a risk of acute
withdrawal) and history of opioid overdose, soon after intake.
☐ Educate individuals on treatment choices and the process for continuation of access to MOUD/MAUD
during incarceration and upon release.
☐ Make available and offer treatment using some formulation of methadone, buprenorphine, or naltrexone
based on a mutually agreed-upon plan between the prescriber and the individual. The plan must take
into consideration, among other clinically relevant factors, the availability of specific medications at their
residence of release.
• Contractor may provide naltrexone or buprenorphine in oral formulation, with or without naloxone
while the individual is incarcerated but must offer an oral formulation of buprenorphine WITH
naloxone unless there is a clinical reason not to do so, e.g., the individual is allergic to naloxone at
release.
☐ Contractor shall not allow an individual to undergo opioid withdrawal, including withdrawal using a
tapering dose of buprenorphine or methadone, unless the individual provides an Informed Refusal of
continuing maintenance MOUD treatment after withdrawing or the individual elects MOUD treatment
with naltrexone.
• In either case, Contractor will offer the individual tapering doses of buprenorphine or methadone
supplemented, as necessary, with alpha-2 adrenergic agonists (e.g., lofexidine), anti-emetics, anti-
diarrheals, analgesics, fluid and electrolyte replacement (e.g., Gatorade®)).
• Initiation of buprenorphine or methadone, whether for maintenance or for withdrawal, must not be
delayed for administrative reasons, e.g., unavailability of a prescriber, beyond when they are
clinically indicated to be started.
2. DURING INCARCERATION
☐ Offer initiation of maintenance MOUD/MAUD to individuals who did not start MOUD/MAUD for acute
opioid or alcohol withdrawal as identified at intake, e.g., individuals with OUD but without physical
dependence, or individuals with AUD who underwent withdrawal.
• For all individuals initiation should begin soon enough to attempt stabilization of dosing prior to
release.
• For individuals with a history of opioid overdose, initiation should begin as soon as possible after
identified.
☐ Educate individuals on treatment choices and the process for continuation of access to MOUD/MAUD
during incarceration and upon release.
☐ Contractor shall not use alternate-day or “balloon” dosing of buprenorphine (i.e., administering a dose
of medication on one (1) day which is intended to last for two (2) or more days).
☐ Administer methadone and buprenorphine more often than one dose daily if clinically necessary, e.g.,
in some pregnant or post-partum individuals, those who metabolize the medication faster, and
individuals who have side effects from large single doses.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 12 of 13
☐ Offer counseling to individuals for their OUD/AUD if they are expected to remain in jail for longer than
one (1) month. Provide MOUD/MAUD regardless of the individual’s willingness to participate in
counseling.
☐ There may be reasons an individual will not continue MOUD/MAUD in the community, such as no
available treatment provider in the community to which the individual is released. If the individual will
not continue MOUD/MAUD in the community, the decision when or if to discontinue MOUD/MAUD prior
to release must be based on a mutually agreed-upon decision between the individual and the
prescriber and must consider factors, including but not limited to, the risks of opioid misuse or overdose
during incarceration, and the individual's willingness to receive a four-week (4-week) dose of an
extended-release injectable buprenorphine just prior to release which will provide a safe, tapered
withdrawal.
3. RELEASE
Contractor must accomplish the following prior to each individual’s release from jail:
☐ Complete release planning and reentry coordination as soon as possible after admission to ensure an
effective plan is in place prior to release, including in the event of an unexpected release of an
individual who needs continued treatment and services.
☐ Provide at least two (2) doses of an opioid reversal agent (e.g., naloxone or Narcan®) and training on
how to administer the medication to all individuals with OUD.
☐ Schedule the first community appointment with a treatment facility for continuation of MOUD or MAUD.
☐ Provide in hand, upon release, and at no cost to the individual, a sufficient number of doses of MOUD
and/or MAUD to bridge the individual until the scheduled MOUD/MAUD follow-up appointment at the
selected community treatment facility.
• If an individual is on a long-acting injectable medication, the Contractor will ensure the timing of the
injectable medication ensures sustained treatment effect to bridge the individual to the scheduled
MOUD/MAUD follow-up appointment at the selected community treatment facility.
• If an individual is at risk of being released directly from court, inform them prior to going to court that
they may request to be transported back to jail by staff to receive these medications prior to going
home.
• In situations where a follow-up appointment upon release cannot be made, e.g., after-hours bail-
out, give the individual enough medication to last until the next available appointment at the
community treatment. If the appointment date is unknown or cannot be reliably estimated, give the
individual a 30-day supply at minimum.
• In situations where medications cannot be provided upon release, e.g., unscheduled release at a
time when medical staff are not present in jail, Contractor must ensure the following:
o The individual is informed that they may either return to the jail in the morning to receive bridge
medications; or
o If no medical staff are present the following day, call in a prescription for the same bridge
medication to a local pharmacy, at no cost to the individual.
☐ Assist Medicaid-eligible individuals to sign up for Medicaid or assist individuals whose Medicaid
coverage has been terminated to reestablish coverage.
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04
HCA Contract No. K5885-05 Page 13 of 13
☐ For any individual with Medicaid coverage, work cooperatively with the individual’s Managed Care
Organizations (MCO) to facilitate re-entry benefits and continued treatment with a community partner,
including but not limited to allowing the MCO’s agent timely access to the jail and the individual.
4. NOTES:
I attest that the general requirements of the MOUD/MAUD in Jails contract have been met as indicated herein.
AUTHORIZED REPRESENTATIVE SIGNATURE PRINTED NAME AND TITLE DATE SIGNED
Docusign Envelope ID: 700826AD-3CE3-815C-8194-013EF364AA04